Breaking News Instant updates and real-time market news.

ONCS

OncoSec

$0.83

-0.9 (-52.02%)

, MRK

Merck

$73.73

0.62 (0.85%)

12:13
11/06/18
11/06
12:13
11/06/18
12:13

OncoSec price target lowered to $3 from $5 at Piper Jaffray

After OncoSec (ONCS) reported preliminary Phase 2b KEYNOTE-695 data for Tavo combined with Merck's (MRK) Keytruda in PD-1 refractory melanoma patients, Piper Jaffray analyst Edward Tenthoff said the data, while early, show evidence of clinical activity, adding that he believes duration of response data will be important. However, OncoSec shares are down 52% today, which Tenthoff attributes to the lower response rate compared to prior data in different patients. The analyst keeps an Overweight rating on OncoSec shares, but lowered his price target on the stock to $3 from $5 as he pushed out his approval projections for Tavo by one year in the U.S. and Europe.

ONCS

OncoSec

$0.83

-0.9 (-52.02%)

MRK

Merck

$73.73

0.62 (0.85%)

  • 06

    Nov

  • 07

    Nov

  • 27

    Nov

  • 11

    Jan

  • 16

    Feb

ONCS OncoSec
$0.83

-0.9 (-52.02%)

02/09/18
PIPR
02/09/18
INITIATION
Target $4
PIPR
Overweight
OncoSec initiated with an Overweight at Piper Jaffray
Piper Jaffray analyst Charles Duncan started OncoSec Medical with an Overweight rating and $4 price target. The company's lead candidate ImmunoPulse in checkpoint inhibitor refractory metastatic melanoma "offers a differentiated approach," the analyst contends. He sees potential for $350M in peak U.S. revenues for IP IL-12 in this initial population following a 2020 launch.
08/14/18
PIPR
08/14/18
NO CHANGE
Target $5
PIPR
Overweight
OncoSec price target raised to $5 from $4 at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff raised his price target for OncoSec Medical to $5 saying tavokinogene telseplasmid has demonstrated proof-of-concept data in relapsed/refractory melanoma. The analyst expects final Phase II OMS-100 monotherapy plus preliminary Phase IIb data at the Society for Immunotherapy of Cancer meeting in November. Depending upon the strength of data in Stage 2 of this trial, OncoSec may be able to seek accelerated approval in melanoma in 2020, Tenthoff tells investors in a research note after taking over coverage of the name. He maintains Piper's Overweight rating on OncoSec.
10/15/18
PIPR
10/15/18
NO CHANGE
Target $5
PIPR
Overweight
Piper reiterates Overweight on OncoSec with $5 price target
Piper Jaffray analyst Edward Tenthoff reiterates an Overweight rating on OncoSec Medical with a $5 price target after the company announced it initiated a Phase II study of tavokinogene telseplasmid plus Keytruda in and triple negative breast cancer patients who have received one prior chemo or immunotherapy with preliminary data in 2019. The primary driver for OncoSec shares remains the Stage 1 Phase IIb Pisces data on tavokinogene telseplasmid plus Keytruda in PD-1 refractory melanoma in November, Tenthoff tells investors in a research note. He points out that depending on the data, OncoSec may initiate Stage 2 of the study, which could serve as the basis for accelerated approval in melanoma in 2020.
MRK Merck
$73.73

0.62 (0.85%)

10/22/18
BMOC
10/22/18
NO CHANGE
Target $82
BMOC
Outperform
Merck price target raised to $82 from $70 at BMO Capital
BMO Capital analyst Alex Arfaei raised his price target on Merck to $82 and kept his Outperform rating, also raising his FY18 EPS view by 18c to $4.01 and FY19 view by 27c to $4.29. The analyst cites his increased confidence around the long-term growth potential of Keytruda and Gardasil and anticipates the company's revenue growing by mid-single digits until the loss of exclusivity for its Januvia program in 2022-23. Arfaei adds that his long-term forecasts are more bullish relative to the Street, with an added catalyst coming from Merck's potential diversification into Animal Health.
10/23/18
WOLF
10/23/18
INITIATION
Target $90
WOLF
Outperform
Merck reinitiated with an Outperform at Wolfe Research
Wolfe Research analyst Time Anderson reinitiated Merck with an Outperform and $66 price target.
10/25/18
WELS
10/25/18
NO CHANGE
WELS
Wells Fargo says Trump speech today won't be end of drug pricing proposals
Wells Fargo analyst David Maris notes that Politico and other media outlets are reporting that President Donald Trump will propose several new initiatives to address high drug prices when he speaks later today at the U.S. Department of Health and Human Services. Maris thinks Trump's focus will be on how other countries are "freeloading" on U.S. innovation with lower negotiated pricing, stating that news reports make it appear that the administration is targeting the industry for action, rather than other countries to raise their spending. While Maris acknowledges the timing of the speech being near the mid-term elections, he believes these proposals are simply the follow-though of earlier promises. He also expects this is not the end of proposals to address the issue of U.S. drug pricing. Publicly traded large-cap drugmakers include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).
10/31/18
SBSH
10/31/18
NO CHANGE
Target $84
SBSH
Buy
Merck price target raised to $84 from $79 at Citi
Citi analyst Andrew Baum raised his price target for Merck to $84 and reiterates a Buy rating on the shares. The analyst says his 20%-plus above consensus non-GAAP earnings estimates beyond 2022 are driven by a continued view that the market underestimates Merck's market share in the PDx and PARP spaces with Keytruda and Lynparza respectively.

TODAY'S FREE FLY STORIES

$NYE

NYSE Market Internals

$0.00

(0.00%)

14:16
02/20/19
02/20
14:16
02/20/19
14:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ETSY

Etsy

$54.65

-0.65 (-1.18%)

14:15
02/20/19
02/20
14:15
02/20/19
14:15
Options
Etsy put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 25

    Feb

  • 07

    Mar

  • 07

    Mar

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$278.60

0.71 (0.26%)

14:09
02/20/19
02/20
14:09
02/20/19
14:09
General news
'Almost all' Fed members wanted to announce plan to stop reducing assets »

Minutes from the last…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$278.60

0.71 (0.26%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$278.27

0.38 (0.14%)

14:06
02/20/19
02/20
14:06
02/20/19
14:06
General news
Fed saw 'variety of considerations' for 'patient approach to monetary policy' »

Minutes from the last…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$278.27

0.38 (0.14%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$278.32

0.43 (0.15%)

14:05
02/20/19
02/20
14:05
02/20/19
14:05
General news
Fed to continue monitoring economic developments for outlook implications »

Minutes from the last…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$278.32

0.43 (0.15%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$278.34

0.45 (0.16%)

14:02
02/20/19
02/20
14:02
02/20/19
14:02
General news
Fed sees 'sustained expansion of economic activity' as most likely outcome »

Minutes from the last…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$278.34

0.45 (0.16%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FDP

Fresh Del Monte

$29.97

0.7 (2.39%)

14:00
02/20/19
02/20
14:00
02/20/19
14:00
Hot Stocks
Breaking Hot Stocks news story on Fresh Del Monte »

Fresh Del Monte trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BHC

Bausch Health

$23.13

-2.04 (-8.10%)

14:00
02/20/19
02/20
14:00
02/20/19
14:00
Options
Dip buyer in Bausch Health Companies »

Dip buyer in Bausch…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 20

    Feb

  • 25

    Feb

  • 25

    Feb

  • 25

    Feb

  • 12

    Mar

  • 12

    Mar

VLKAY

Volkswagen

$0.00

(0.00%)

, AUDVF

Audi AG

$0.00

(0.00%)

13:59
02/20/19
02/20
13:59
02/20/19
13:59
Periodicals
Audi plans to cut 10% of management positions, Reuters reports »

Audi (AUDVF),…

VLKAY

Volkswagen

$0.00

(0.00%)

AUDVF

Audi AG

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TTD

Trade Desk

$146.31

-15.45 (-9.55%)

13:58
02/20/19
02/20
13:58
02/20/19
13:58
On The Fly
Trade Desk slides after analyst cuts rating ahead of quarterly results »

Shares of Trade Desk…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 21

    Feb

  • 06

    Mar

  • 06

    Mar

UA

Under Armour

$19.15

-0.23 (-1.19%)

13:55
02/20/19
02/20
13:55
02/20/19
13:55
Options
Under Armour put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Mar

  • 06

    Mar

PM

Philip Morris

$85.42

2 (2.40%)

13:50
02/20/19
02/20
13:50
02/20/19
13:50
Earnings
Philip Morris repeats Q1 reported diluted EPS view of $1.00, consensus $1.01 »

As communicated on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PM

Philip Morris

$85.42

2 (2.40%)

13:49
02/20/19
02/20
13:49
02/20/19
13:49
Earnings
Philip Morris reaffirms FY19 reported diluted EPS guidance of at least $5.37 »

Philip Morris…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:45
02/20/19
02/20
13:45
02/20/19
13:45
General news
Fed's Kaplan said a weaker business outlook is the reason for caution on rates »

Fed's Kaplan said a…

13:45
02/20/19
02/20
13:45
02/20/19
13:45
General news
Breaking General news story  »

FOMC Minutes to be…

MDR

McDermott

$7.80

0.44 (5.98%)

13:40
02/20/19
02/20
13:40
02/20/19
13:40
Options
Bullish option play in McDermott as shares rally ahead of earnings »

Bullish option play in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 25

    Feb

  • 04

    Mar

  • 05

    Mar

  • 12

    Mar

  • 17

    Mar

  • 18

    Mar

  • 02

    May

STAG

STAG Industrial

$28.24

-0.59 (-2.05%)

13:34
02/20/19
02/20
13:34
02/20/19
13:34
Recommendations
STAG Industrial analyst commentary  »

STAG Industrial price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GOOG

Alphabet

$1,118.00

-0.16 (-0.01%)

, GOOGL

Alphabet Class A

$1,125.12

-1.31 (-0.12%)

13:28
02/20/19
02/20
13:28
02/20/19
13:28
Periodicals
Epic Games stops 'Fortnite' pre-roll ads on YouTube due to predators, Verge says »

Epic Games is no longer…

GOOG

Alphabet

$1,118.00

-0.16 (-0.01%)

GOOGL

Alphabet Class A

$1,125.12

-1.31 (-0.12%)

TCEHY

Tencent

$0.00

(0.00%)

DIS

Disney

$113.63

0.11 (0.10%)

KKR

KKR

$23.52

-0.2 (-0.84%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 25

    Feb

  • 27

    Feb

  • 03

    Mar

  • 07

    Mar

  • 18

    Mar

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$278.00

0.11 (0.04%)

13:28
02/20/19
02/20
13:28
02/20/19
13:28
Periodicals
Barr could announce end of Mueller investigation next week, CNN reports »

Attorney General Bill…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$278.00

0.11 (0.04%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OMI

Owens & Minor

$6.40

-1.54 (-19.40%)

13:24
02/20/19
02/20
13:24
02/20/19
13:24
Periodicals
Owens & Minor working with banks to explore sale, Reuters reports »

Owens & Minor is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

OMI

Owens & Minor

$6.41

-1.53 (-19.27%)

13:20
02/20/19
02/20
13:20
02/20/19
13:20
Hot Stocks
Breaking Hot Stocks news story on Owens & Minor »

Owens & Minor trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

OMI

Owens & Minor

$6.41

-1.53 (-19.27%)

13:18
02/20/19
02/20
13:18
02/20/19
13:18
Hot Stocks
Breaking Hot Stocks news story on Owens & Minor »

Owens & Minor halted…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

GOLD

Barrick Gold

$13.98

0.43 (3.17%)

13:17
02/20/19
02/20
13:17
02/20/19
13:17
Hot Stocks
Barrick Gold confirms commitment to Chile as it reviews LATAM strategy »

The company said,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OMI

Owens & Minor

$6.41

-1.53 (-19.27%)

13:17
02/20/19
02/20
13:17
02/20/19
13:17
Periodicals
Breaking Periodicals news story on Owens & Minor »

Owens & Minor…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

13:17
02/20/19
02/20
13:17
02/20/19
13:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.